| Beth R Schwartz, MD | |
|
6701 N Charles St, Baltimore, MD 21204-6808 | |
| (443) 849-2896 | |
| (443) 849-3016 |
| Full Name | Beth R Schwartz |
|---|---|
| Gender | Female |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 6701 N Charles St, Baltimore, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730119587 | NPI | - | NPPES |
| R2980005 | Other | DC | GHMSI/BLUECHOICE |
| 60266401 | Other | MD | CAREFIRST OF MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | D38352 (Maryland) | Primary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | D38352 (Maryland) | Primary |
| Entity Name | Lifebridge Community Gastroenterology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033558416 PECOS PAC ID: 7618108119 Enrollment ID: O20140326001773 |
News Archive
A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A recent review of research suggests that changes to the microorganisms (microbiota) in the gastrointestinal (GI) tract may be a cause of irritable bowel syndrome (IBS).
Disease-causing bacteria can linger on surfaces commonly found in airplane cabins for days, even up to a week, according to research presented at the annual meeting of the American Society for Microbiology.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beth R Schwartz, MD 6701 N Charles St, Baltimore, MD 21204-6808 Ph: (443) 849-2896 | Beth R Schwartz, MD 6701 N Charles St, Baltimore, MD 21204-6808 Ph: (443) 849-2896 |
News Archive
A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A recent review of research suggests that changes to the microorganisms (microbiota) in the gastrointestinal (GI) tract may be a cause of irritable bowel syndrome (IBS).
Disease-causing bacteria can linger on surfaces commonly found in airplane cabins for days, even up to a week, according to research presented at the annual meeting of the American Society for Microbiology.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
› Verified 9 days ago
Serena Maria Bagnasco, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-955-2660 | |
Dr. Adeboye Oluwaseyi Osunkoya, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 N Broadway, Johns Hopkins Pathology , Weinberg Room 2242, Baltimore, MD 21231 Phone: 405-808-5361 | |
Michael T. O'malley, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2401 W Belvedere Ave, Baltimore, MD 21215 Phone: 410-644-4379 Fax: 410-644-4325 | |
Michael Edward Kallen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 N Broadway St, Baltimore, MD 21287 Phone: 410-955-3580 Fax: 410-614-1287 | |
Deyin Xing, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 401 North Broadway, Weinberg 2268, Baltimore, MD 21231 Phone: 410-955-3580 Fax: 410-614-1287 | |
Matthew Grant Gabrielson, Pathology Medicare: Medicare Enrolled Practice Location: 600 N Wolfe St, Baltimore, MD 21287 Phone: 410-955-3980 | |
Robert A. Palermo, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 6701 N Charles St, Baltimore, MD 21204 Phone: 443-849-2257 Fax: 443-849-3016 |